New pill shows promise for advanced breast cancer – Real-World trial underway
NCT ID NCT05578053
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing a new oral drug called dalpiciclib in 420 people with hormone receptor-positive advanced breast cancer. Researchers are watching how well it works and what side effects occur in everyday medical practice, not a strict lab setting. The goal is to see if it can help control the disease longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dalpiciclib (a CDK4/6 inhibitor pill)
What this could lead to
If successful, this could show that dalpiciclib is a safe and effective option for controlling advanced HR+ breast cancer in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage and may not lead to a new standard of care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth hospital of Hebei University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••